New drug combo aims to stop lung Cancer's return
NCT ID NCT06606847
First seen Nov 01, 2025 · Last updated Jun 19, 2026 · Updated 39 times
Summary
This phase 2 trial tests two drugs, durvalumab and oleclumab, given together after standard chemoradiation in 30 people with stage III lung cancer that cannot be removed by surgery. The goal is to see if the combination can delay cancer progression. Participants must have stable disease after chemoradiation and meet specific health criteria.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
Kazan', 420029, Russia
-
Research Site
Moscow, 111123, Russia
-
Research Site
Moscow, 115478, Russia
-
Research Site
Moscow, 143423, Russia
-
Research Site
Nizhny Novgorod, 603126, Russia
-
Research Site
Novosibirsk, 630108, Russia
-
Research Site
Obninsk, 249031, Russia
-
Research Site
Saint Petersburg, 197022, Russia
-
Research Site
Saint Petersburg, 197758, Russia
-
Research Site
Ufa, 450054, Russia
-
Research Site
Yekaterinburg, 620905, Russia
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
durvalumab and oleclumab (two drugs given by IV infusion)
What this could lead to
If it works, this combination could help keep stage III lung cancer from growing back after initial chemoradiation.
What could go wrong
This is a small, early-phase trial with only 30 people and no comparison group. The drugs may cause side effects and may not improve outcomes.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.